Aims: Few studies have analysed the presence of hearing abnormalities in diabetes. We assessed the presence of subclinical auditory alterations and their possible association with early vascular and neurological dysfunction in young adults with Type 1 diabetes of long duration.
Methods: Thirty-one patients with Type 1 diabetes (mean age 33 ± 2.3 years, disease duration 25.7 ± 4.2 years) and 10 healthy controls underwent pure tone audiometry (PTA), distortion product otoacoustic emission (DPOAE) and auditory brainstem response (ABR) analyses. Associations with metabolic variables and chronic complications were explored.
Results: Compared with healthy controls, patients with diabetes had significantly higher mean hearing thresholds, although still within the normoacusic range. DPOAE intensities at medium frequencies (2.8-4 kHz) were significantly lower in patients with diabetes. In ABR, in addition to waves I, III and V, we observed the appearance of a visible wave IV in patients with diabetes compared with controls (prevalence 61% vs. 10%, P < 0.05), and its appearance was related to a prolonged I-V interval (4.40 ± 0.62 ms vs. 4.19 ± 0.58 ms, P < 0.05). Diastolic blood pressure was higher in people with abnormal DPOAE (P < 0.05), whereas systolic blood pressure correlated with wave V and interpeak I-V interval latencies. A trend towards an association between evidence of wave IV and the presence of somatic neuropathy or abnormal cardiovascular autonomic tests was observed.
Conclusions: Young adults with long-term Type 1 diabetes have subclinical abnormalities in qualitative auditory perception, despite normal hearing thresholds, which might reflect neuropathic and/or vascular alterations.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/dme.13039 | DOI Listing |
Child Health Care
June 2023
Center for Technology and Behavioral Health, Geisel School of Medicine, Dartmouth College, Lebanon, NH, USA.
We examined if anxiety/depression, delay discounting (DD), and their interaction were associated with greater A1c levels and reduced medical adherence in adolescents with type 1 diabetes (T1D). Sixty-one adolescents with T1D completed a DD task and an A1c blood test. Adherence was assessed by self-monitoring of blood glucose (SMBG) using glucometer data.
View Article and Find Full Text PDFInt J Health Sci (Qassim)
January 2025
Department of Food Science and Human Nutrition, College of Agriculture and Food, Qassim University, 51452 Buraidah, Saudi Arabia.
Objective: The current study was conducted to investigate the effect of intermittent fasting (IF) with a low-carbohydrate-high-protein (LCHP) diet on blood glucose control in streptozotocin (STZ)-nicotinamide-induced type 2 diabetic rats (DR).
Methods: Thirty male Wistar rats were divided into six groups ( = 5) including a group of normal rats (NR) that received a control diet (CD) (50% carbohydrates, 17% protein, and 33% fat) with (AL) feeding. The remaining 5 groups were DR injected with STZ and fed on CD or LCHP diet (40% carbohydrates, 30% protein, and 30% fat) for 6 weeks, either AL or IF (with a time-restricted feeding of 16 h followed by 8 h feeding period).
Front Clin Diabetes Healthc
December 2024
Department of Basic Sciences, College of Medicine, Sulaiman Al Rajhi University, Al-Bukairyah, Saudi Arabia.
Background: Complications of diabetes and its associated comorbidities can cause rapid progression of type II diabetes mellitus (T2DM). It comes at high costs and affects a patient's quality of life. We aim to assess T2DM in KSA, including the demographics, medications, complications, and comorbidities, as it remains an integral part of Vision 2030.
View Article and Find Full Text PDFInt J Gen Med
December 2024
Department of Thoracic Surgery, The First Affiliated Hospital of Soochow University, Suzhou, 215006, People's Republic of China.
Purpose: To further identify the clinical impact of metformin on the prognosis of non-small cell lung cancer (NSCLC) with type 2 diabetes who received immunotherapy.
Methods: Stage IV NSCLC patients with type 2 diabetes receiving the immunotherapy from 2017 to 2021 were retrospectively enrolled and divided into the metformin group or non-metformin group according to the treatment strategy for type 2 diabetes (metformin vs other hypoglycemic medicines). The overall response rate (ORR) was primary endpoint, and overall survival (OS), progression-free survival (PFS) and disease control rate (DCR) were secondary endpoints.
Lancet Reg Health Eur
January 2025
Usher Institute, University of Edinburgh, UK.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!